MediWound Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by MediWound Ltd., a foreign private issuer, for the month of October 2019. The filing serves to distribute a press release dated October 2, 2019, regarding a strategic collaboration with Vericel Corporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the initiation of a U.S. Expanded Access Treatment Protocol for the Company's product, NexoBrid, in collaboration with Vericel. This protocol allows for the use of NexoBrid in patients with severe burns who do not qualify for clinical trials.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the expanded access protocol. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the context of the press release attached as Exhibit 99.1.
Key Facts for Investor Verification
- MediWound and Vericel have initiated a U.S. Expanded Access Treatment Protocol for NexoBrid.
- The filing date is October 2, 2019.
- No financial performance data is included in this specific filing.
- Investors should review the attached press release (Exhibit 99.1) for details on the protocol's scope and eligibility criteria.